CLAIMS

What is claimed is:

1. Use of an effective amount of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound **1**) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating renal anemia secondary to or associated with chronic kidney disease in a subject,

wherein the effective amount of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound **1**) or a pharmaceutically acceptable salt thereof is to be given at least 1 hour or at least 2 hours before and/or after taking a second pharmaceutical composition selected from a calcium-containing composition, a magnesium-containing composition, a lanthanum-containing composition, or an aluminum-containing composition,

wherein:

the calcium-containing composition comprises oral calcium acetate or calcium carbonate; and

the lanthanum-containing composition is an oral lanthanum carbonate.

2. The use of claim 1, wherein the second pharmaceutical composition is a calcium-containing composition comprising oral calcium acetate.

3. The use of claim 1, wherein the second pharmaceutical composition is a calcium-containing composition comprising oral calcium carbonate.

4. The use of any one of claims 1–3, wherein {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound **1**) or a pharmaceutically acceptable salt thereof is to be given at least 2 hours before and/or administration of the second pharmaceutical composition.

5. The use of any one of claims 1-3, wherein {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound **1**) or a pharmaceutically acceptable salt thereof is to be given at least 1 hour before administration of the second pharmaceutical composition.

6. The use of any one of claims 1-5, wherein the chronic kidney disease is dialysis-dependent chronic kidney disease (DD-CKD) or non dialysis-dependent chronic kidney disease (NDD-CKD).

7. The use of claim 6, wherein the chronic kidney disease is DD-CKD.

8. The use of claim 6, wherein the chronic kidney disease is NDD-CKD.

9. The use of any one of claims 1-8, wherein the subject is to be administered a daily dose of 150-600 mg of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid (Compound **1**) or a pharmaceutically acceptable salt thereof.